MedCity Pivot Podcast: Modernizing Prior Auth
In this episode, MedCity News' Arundhati Parmar chats with a pharmacy benefits leader and a virtual pharmacy operator about ways to modernize and scale prior authorization.
presented by
presented by
MedCity Pivot Podcast: Assessing the Hype and Healthcare Potential of AI and the Guardrails Needed to Prevent Medical Errors
Joining the conversation are Serge Perras of Abarca Health; Ton Roelandse with Trexin Consulting; and Bertil Chappuis of Xtillion.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
presented by
MedCity Pivot Podcast: A Flexible Approach to Pharmacy Benefits Management
Pharmacy benefit managers are under scrutiny for their business practices that are often blamed for contributing to the rising costs of prescription drugs in America. But one PBM is paving another way that alters the traditional operating model.
presented by
Pharmacy as the Front Line of the Consumer Experience Revolution
In an interview, Abarca President and COO Adriana Ramirez shared why the future of healthcare must prioritize the human experience, powered by technology.
presented by
MedCity Pivot Podcast: Price Transparency is the New North in the PBM World
In this episode, a pharmacy benefit management executive and a pharmacy startup talk about why benefit verification, prior authorizations, and patient affordability still break the workflow and how smart integrations, real-time eligibility, and intuitive design can reduce friction for all involved.
presented by
AI Is at the Heart of PBM Evolution
In an interview, Abarca Chief Information Officer Serge Perras discussed how Abarca is implementing AI and where he sees the most value for PBMs.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
presented by
How AI, Analytics, and Collaboration Can Solve Specialty Drug Spending Challenges
Nicole Bulochnik, Abarca Senior Vice President of Drug Value Strategy, explained how AI, analytics, and cross-sector collaboration can transform specialty drug costs.
presented by
Are GLP-1 Drugs Here to Stay?
We recently spoke with Nicole Bulochnik, senior vice president of drug strategy for Abarca, about what payers need to consider as demand for this group of weight-loss drugs remains high.
presented by
How AI and Machine Learning Can Transform Pharmacy Benefits Management
Abarca executives see plenty of potential for new technologies but note the need to strike the right balance between tech and human intervention.
presented by
Unlocking Transparency in PBM Pricing
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
presented by
The PBM Model of the Future: Why Payers Are Unbundling PBM Services
Javier Gonzalez, Chief Growth and Commercial Officer at Abarca, about why payers are increasingly looking for alternatives to the traditional PBM model.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
presented by
What Do Payers Need to Help Value-Based Contracting Deals for Novel Therapies Succeed?
A panel discussion at the annual Abarca Forward conference in Puerto Rico last month sought to identify some of the innovative financial approaches that can be applied to managing the high price of novel therapies. Conversations also addressed what payers need for these financing models to be sustainable.